European Court Cancels Biogen's Extended Market Exclusivity for Multiple Sclerosis Drug Tecfidera
Key Insights
The European General Court overturned a European Commission decision that would have extended Biogen's market exclusivity for Tecfidera from ten to eleven years, ruling that strict eight-year deadlines cannot be extended due to case complexity.
The court's ruling establishes that generic drug manufacturers need clarity on market entry timelines and that regulatory authorities cannot exercise discretion to bypass statutory time limits under Article 14(11) of Regulation 726/2004.
Biogen continues to fight multiple patent disputes across European countries including Germany, Netherlands, and France through preliminary injunction proceedings to protect its formulation patent EP 2 653 873 covering dimethyl fumarate compositions.
The European General Court has delivered a significant blow to Biogen's efforts to maintain market exclusivity for its multiple sclerosis drug Tecfidera, overturning a European Commission decision that would have extended the company's protection period. The ruling establishes strict interpretation of regulatory deadlines and provides clarity for generic manufacturers seeking market entry.
Court Rejects Commission's Extension Decision
The General Court ruled that the eight-year time limit specified in Article 14(11) of Regulation 726/2004 is absolute and cannot be extended based on case complexity arguments. The European Commission had previously granted Biogen an extension from ten to eleven years of market exclusivity, citing the complexity of the case as justification for exceeding the statutory eight-year deadline for approving new therapeutic indications.
The court designated case T-256/23 as a pilot case and expanded its bench from three to five judges, including the vice president, for an oral hearing held on December 10, 2024. On the same day, the court delivered nearly identical decisions in seven related cases: T-257/23, T-258/23, T-278/23, T-299/23, T-309/23, T-351/23, and T-393/23.
Implications for Generic Market Entry
The General Court emphasized that generic drug manufacturers require certainty about when they can enter the market, rejecting the Commission's argument that complex cases warrant deadline extensions. The ruling overturned Commission Implementing Decision C(2023) 3067 (final) of May 2, 2023, which had amended the marketing authorization for Tecfidera under Directive 2001/83/EC.
While the court effectively cancelled Biogen's additional year of market protection, this extended period had already expired in February 2025. The decision may create opportunities for generic manufacturers such as Mylan or Viatris to pursue damages claims, though it remains unclear whether such actions will be initiated.
Ongoing Patent Disputes Across Europe
Despite the market exclusivity setback, Biogen continues to pursue patent protection through preliminary injunction proceedings in multiple European jurisdictions, including Germany, the Netherlands, and France. These disputes center on formulation patent EP 2 653 873, which protects pharmaceutical compositions comprising dimethyl fumarate or monomethyl fumarate plus pharmaceutically acceptable excipients, administered in a 480mg daily dose.
The patent landscape has shown mixed results for Biogen across different countries. In June, the Paris Judicial Court ruled that the French portion of EP 873 was invalid due to lack of inventive step, finding that Mylan and Viatris had not infringed the patent. The court ordered Biogen to pay €300,000 plus legal costs to the generic manufacturers. Biogen also suffered defeat in Dutch proceedings in early 2025.
German Court Proceedings Continue
Düsseldorf Higher Regional Court is currently hearing appeals against preliminary injunctions that were granted to prevent generic manufacturers from entering the German market with Tecfidera alternatives. The appeals involve major competitors including Mylan/Viatris, Ratiopharm (search), Stada (search), Aliud Pharma, and Hexal (search) under case IDs I-2 U 32/25, I-2 U 33/25, I-2 U 34/25, and I-2 U 36/25.
In 2022, Biogen had initially lost the main proceedings at first instance due to validity concerns over the patent amid pending European Patent Office (EPO) oppositions. However, after the EPO Opposition Division upheld the patent in December 2024, Biogen successfully obtained ex-parte preliminary injunctions from Düsseldorf Regional Court at the end of 2024.
EPO Opposition Proceedings
The patent faces significant opposition at the European Patent Office, with a lengthy list of opponents including major generic manufacturers. The EPO Opposition Division upheld the patent in December 2024, but opponents have filed appeals that will be heard by the Boards of Appeal from November 25-27, 2025, under case ID T1462/24-3.3.04.
Legal Representation and Next Steps
Both the European Commission and Biogen retain the right to appeal the General Court's market exclusivity decision to the European Court of Justice. Parallel legal disputes concerning initial marketing authorizations for generic versions also continue across multiple jurisdictions.
The ruling represents a significant precedent for pharmaceutical market exclusivity cases, establishing that regulatory authorities cannot exercise discretion to extend statutory deadlines regardless of case complexity, potentially affecting future decisions involving other pharmaceutical companies seeking extended market protection.